EMA seeks stakeholder input on new reflection paper to reduce and replace non‑human primate use in medicines safety testing through 3Rs approaches.

EMA public consultation on non‑human primate use in safety testing

Non-human primate hand via pickpik.com (CC0)

The European Medicines Agency (EMA) has launched a public consultation on a draft “Reflection paper on non-human primates in safety testing of human medicinal products and opportunities for 3Rs implementation”.

The reflection paper provides an overview of the scientific and regulatory considerations for using non‑human primates (NHPs) in the safety testing of human medicinal products. It reviews current uses, highlights existing flexibility in applying the 3Rs principles (Replacement, Reduction and Refinement), and points to emerging alternatives that could further reduce or replace NHP use in the future.

NHPs should be used for regulatory safety testing only as a last resort. The document outlines current opportunities to reduce, refine or replace their use in pharmaceutical development and describes scientific advances that may soon gain broader regulatory acceptance.

Progress in novel, including non‑animal, approaches is scientifically and ethically essential and will depend on continued innovation, collaboration and proactive regulatory engagement.

The draft document is open for consultation, and stakeholders can provide input until 31 January 2026 via the EMA website: Non-human primates in safety testing of human medicinal products and opportunities for 3Rs implementation – scientific guideline.

News & Updates

You might also be interested in

Picture for the website (1)

New survey launched to improve rare diseases clinical trial enrolment

The RealiseD project launched a new multi-stakeholder survey that invites the rare disease community to share insights and help improve clinical trial enrolment
Advancement of Treatments for Rare Diseases

Advancement of Treatments for Rare Diseases

The two-day event will focus on translating research and policy initiatives into tangible benefits for Rare Disease patients through better prevention, diagnosis, and treatment.
RealiseD webinars

RealiseD webinar series: Helping re‑shape rare disease clinical trials

13 January – 10 February 2026 | Online webinar series to advance best practices in clinical trial design for rare and ultra rare diseases.
Molecular therapy

Tailored antisense oligonucleotides for ultrarare CNS diseases: An experience-based best practice framework for individual patient evaluation

Outside traditional drug development pathways, clinicians and scientists face the challenge of systematically evaluating whether individual patients with severe ultrarare diseases might be eligible for and potentially benefit from individualized mutation-specific RNA therapies.

ERDERA's

search form